Cohort . | Subject ID . | Dosing . | C1D8 . | C1D15 . | C1D22 . | C2D1 . | C3D1 . | C4D1 . | EOT . |
---|---|---|---|---|---|---|---|---|---|
Cohort 1: 80 mg q4d | 002 | pre | 8.751 | — | — | 11.693 | — | — | <LLOQ (EoC2) |
post | 12.323 | — | — | — | — | — | — | ||
003 | pre | <LLOQ | — | 17.318 | — | — | — | — | |
post | <LLOQ | — | 30.096 | — | — | — | — | ||
004 | pre | <LLOQ | — | — | <LLOQ | — | — | — | |
post | <LLOQ | — | — | — | — | — | — | ||
Cohort 2: 120 mg q4d | 005 | pre | — | — | — | 7.18 | — | — | — |
post | — | 37.68 | — | — | — | — | — | ||
006 | pre | — | <LLOQ | — | 10.104 | <LLOQ | 11.223 | — | |
post | — | 66.156 | — | — | — | — | — | ||
008 | pre | 22.243 | — | — | — | — | — | — | |
post | 392.01 | — | — | — | — | — | — | ||
Cohort 3: 180 mg q4d | 010 | pre | — | — | 43.226 | — | — | — | — |
post | — | — | 324.265 | — | — | — | — | ||
011 | pre | 11.616 | — | — | — | 19.265 | — | — | |
post | 11.705 | — | — | — | — | — | — | ||
012 | pre | — | <LLOQ | — | <LLOQ | — | — | 6.402 (EoC4) | |
post | — | 96.354 | — | 85.834 | — | — | — | ||
013 | pre | — | 10.374 | — | 41.964 | — | 6.787 | — | |
post | — | — | — | — | — | — | — | ||
Expansion Cohort 3: 180 mg q4d | 014 | pre | 11.442 | — | — | — | — | — | — |
post | 60.605 | — | — | — | — | — | — | ||
017 | pre | — | 10.425 | - | 5.708 | <LLOQ | 6.264 | - | |
post | — | 89.884 | — | — | — | — | — | ||
Cohort 4: 280 mg q7d | 015 | pre | — | <LLOQ | — | — | — | — | <LLOQ (EoC1) |
post | — | 40.694 | — | — | — | — | — | ||
016 | pre | — | <LLOQ | — | — | — | — | — | |
post | — | 205.634 | — | — | — | — | — | ||
018 | pre | — | 9.603 | — | 22.084 | 14.169 | 11.731 | 10.379 (EoC4) | |
post | — | 322.557 | — | 340.709 | — | — | — | ||
Expansion Cohort 4: 280 mg q7d | 019 | pre | 9.857 | — | — | 11.805 | — | — | <LLOQ (EoC2) |
post | 153.973 | — | — | — | — | — | — | ||
020 | pre | — | 8.586 | — | 11.278 | — | — | — | |
post | — | 110.625 | — | — | — | — | — | ||
021 | pre | — | 5.966 | — | <LLOQ | — | — | <LLOQ (C2D15) | |
post | — | 40.352 | — | — | — | — | — |
Cohort . | Subject ID . | Dosing . | C1D8 . | C1D15 . | C1D22 . | C2D1 . | C3D1 . | C4D1 . | EOT . |
---|---|---|---|---|---|---|---|---|---|
Cohort 1: 80 mg q4d | 002 | pre | 8.751 | — | — | 11.693 | — | — | <LLOQ (EoC2) |
post | 12.323 | — | — | — | — | — | — | ||
003 | pre | <LLOQ | — | 17.318 | — | — | — | — | |
post | <LLOQ | — | 30.096 | — | — | — | — | ||
004 | pre | <LLOQ | — | — | <LLOQ | — | — | — | |
post | <LLOQ | — | — | — | — | — | — | ||
Cohort 2: 120 mg q4d | 005 | pre | — | — | — | 7.18 | — | — | — |
post | — | 37.68 | — | — | — | — | — | ||
006 | pre | — | <LLOQ | — | 10.104 | <LLOQ | 11.223 | — | |
post | — | 66.156 | — | — | — | — | — | ||
008 | pre | 22.243 | — | — | — | — | — | — | |
post | 392.01 | — | — | — | — | — | — | ||
Cohort 3: 180 mg q4d | 010 | pre | — | — | 43.226 | — | — | — | — |
post | — | — | 324.265 | — | — | — | — | ||
011 | pre | 11.616 | — | — | — | 19.265 | — | — | |
post | 11.705 | — | — | — | — | — | — | ||
012 | pre | — | <LLOQ | — | <LLOQ | — | — | 6.402 (EoC4) | |
post | — | 96.354 | — | 85.834 | — | — | — | ||
013 | pre | — | 10.374 | — | 41.964 | — | 6.787 | — | |
post | — | — | — | — | — | — | — | ||
Expansion Cohort 3: 180 mg q4d | 014 | pre | 11.442 | — | — | — | — | — | — |
post | 60.605 | — | — | — | — | — | — | ||
017 | pre | — | 10.425 | - | 5.708 | <LLOQ | 6.264 | - | |
post | — | 89.884 | — | — | — | — | — | ||
Cohort 4: 280 mg q7d | 015 | pre | — | <LLOQ | — | — | — | — | <LLOQ (EoC1) |
post | — | 40.694 | — | — | — | — | — | ||
016 | pre | — | <LLOQ | — | — | — | — | — | |
post | — | 205.634 | — | — | — | — | — | ||
018 | pre | — | 9.603 | — | 22.084 | 14.169 | 11.731 | 10.379 (EoC4) | |
post | — | 322.557 | — | 340.709 | — | — | — | ||
Expansion Cohort 4: 280 mg q7d | 019 | pre | 9.857 | — | — | 11.805 | — | — | <LLOQ (EoC2) |
post | 153.973 | — | — | — | — | — | — | ||
020 | pre | — | 8.586 | — | 11.278 | — | — | — | |
post | — | 110.625 | — | — | — | — | — | ||
021 | pre | — | 5.966 | — | <LLOQ | — | — | <LLOQ (C2D15) | |
post | — | 40.352 | — | — | — | — | — |
Abbreviations: EOT, end of treatment; EoC, end of cycle; q, every; d, days; LLOQ, lower limit of quantitation.
Cohort . | Subject ID . | Dosing . | C1D8 . | C1D15 . | C1D22 . | C2D1 . | C3D1 . | C4D1 . | EOT . |
---|---|---|---|---|---|---|---|---|---|
Cohort 1: 80 mg q4d | 002 | pre | 8.751 | — | — | 11.693 | — | — | <LLOQ (EoC2) |
post | 12.323 | — | — | — | — | — | — | ||
003 | pre | <LLOQ | — | 17.318 | — | — | — | — | |
post | <LLOQ | — | 30.096 | — | — | — | — | ||
004 | pre | <LLOQ | — | — | <LLOQ | — | — | — | |
post | <LLOQ | — | — | — | — | — | — | ||
Cohort 2: 120 mg q4d | 005 | pre | — | — | — | 7.18 | — | — | — |
post | — | 37.68 | — | — | — | — | — | ||
006 | pre | — | <LLOQ | — | 10.104 | <LLOQ | 11.223 | — | |
post | — | 66.156 | — | — | — | — | — | ||
008 | pre | 22.243 | — | — | — | — | — | — | |
post | 392.01 | — | — | — | — | — | — | ||
Cohort 3: 180 mg q4d | 010 | pre | — | — | 43.226 | — | — | — | — |
post | — | — | 324.265 | — | — | — | — | ||
011 | pre | 11.616 | — | — | — | 19.265 | — | — | |
post | 11.705 | — | — | — | — | — | — | ||
012 | pre | — | <LLOQ | — | <LLOQ | — | — | 6.402 (EoC4) | |
post | — | 96.354 | — | 85.834 | — | — | — | ||
013 | pre | — | 10.374 | — | 41.964 | — | 6.787 | — | |
post | — | — | — | — | — | — | — | ||
Expansion Cohort 3: 180 mg q4d | 014 | pre | 11.442 | — | — | — | — | — | — |
post | 60.605 | — | — | — | — | — | — | ||
017 | pre | — | 10.425 | - | 5.708 | <LLOQ | 6.264 | - | |
post | — | 89.884 | — | — | — | — | — | ||
Cohort 4: 280 mg q7d | 015 | pre | — | <LLOQ | — | — | — | — | <LLOQ (EoC1) |
post | — | 40.694 | — | — | — | — | — | ||
016 | pre | — | <LLOQ | — | — | — | — | — | |
post | — | 205.634 | — | — | — | — | — | ||
018 | pre | — | 9.603 | — | 22.084 | 14.169 | 11.731 | 10.379 (EoC4) | |
post | — | 322.557 | — | 340.709 | — | — | — | ||
Expansion Cohort 4: 280 mg q7d | 019 | pre | 9.857 | — | — | 11.805 | — | — | <LLOQ (EoC2) |
post | 153.973 | — | — | — | — | — | — | ||
020 | pre | — | 8.586 | — | 11.278 | — | — | — | |
post | — | 110.625 | — | — | — | — | — | ||
021 | pre | — | 5.966 | — | <LLOQ | — | — | <LLOQ (C2D15) | |
post | — | 40.352 | — | — | — | — | — |
Cohort . | Subject ID . | Dosing . | C1D8 . | C1D15 . | C1D22 . | C2D1 . | C3D1 . | C4D1 . | EOT . |
---|---|---|---|---|---|---|---|---|---|
Cohort 1: 80 mg q4d | 002 | pre | 8.751 | — | — | 11.693 | — | — | <LLOQ (EoC2) |
post | 12.323 | — | — | — | — | — | — | ||
003 | pre | <LLOQ | — | 17.318 | — | — | — | — | |
post | <LLOQ | — | 30.096 | — | — | — | — | ||
004 | pre | <LLOQ | — | — | <LLOQ | — | — | — | |
post | <LLOQ | — | — | — | — | — | — | ||
Cohort 2: 120 mg q4d | 005 | pre | — | — | — | 7.18 | — | — | — |
post | — | 37.68 | — | — | — | — | — | ||
006 | pre | — | <LLOQ | — | 10.104 | <LLOQ | 11.223 | — | |
post | — | 66.156 | — | — | — | — | — | ||
008 | pre | 22.243 | — | — | — | — | — | — | |
post | 392.01 | — | — | — | — | — | — | ||
Cohort 3: 180 mg q4d | 010 | pre | — | — | 43.226 | — | — | — | — |
post | — | — | 324.265 | — | — | — | — | ||
011 | pre | 11.616 | — | — | — | 19.265 | — | — | |
post | 11.705 | — | — | — | — | — | — | ||
012 | pre | — | <LLOQ | — | <LLOQ | — | — | 6.402 (EoC4) | |
post | — | 96.354 | — | 85.834 | — | — | — | ||
013 | pre | — | 10.374 | — | 41.964 | — | 6.787 | — | |
post | — | — | — | — | — | — | — | ||
Expansion Cohort 3: 180 mg q4d | 014 | pre | 11.442 | — | — | — | — | — | — |
post | 60.605 | — | — | — | — | — | — | ||
017 | pre | — | 10.425 | - | 5.708 | <LLOQ | 6.264 | - | |
post | — | 89.884 | — | — | — | — | — | ||
Cohort 4: 280 mg q7d | 015 | pre | — | <LLOQ | — | — | — | — | <LLOQ (EoC1) |
post | — | 40.694 | — | — | — | — | — | ||
016 | pre | — | <LLOQ | — | — | — | — | — | |
post | — | 205.634 | — | — | — | — | — | ||
018 | pre | — | 9.603 | — | 22.084 | 14.169 | 11.731 | 10.379 (EoC4) | |
post | — | 322.557 | — | 340.709 | — | — | — | ||
Expansion Cohort 4: 280 mg q7d | 019 | pre | 9.857 | — | — | 11.805 | — | — | <LLOQ (EoC2) |
post | 153.973 | — | — | — | — | — | — | ||
020 | pre | — | 8.586 | — | 11.278 | — | — | — | |
post | — | 110.625 | — | — | — | — | — | ||
021 | pre | — | 5.966 | — | <LLOQ | — | — | <LLOQ (C2D15) | |
post | — | 40.352 | — | — | — | — | — |
Abbreviations: EOT, end of treatment; EoC, end of cycle; q, every; d, days; LLOQ, lower limit of quantitation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.